Online inquiry

IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7533MR)

This product GTTS-WQ7533MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CLDN18 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001002026.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51208
UniProt ID P56856
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ7533MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4018MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ12217MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ5370MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ9597MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ8273MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HM10560A
GTTS-WQ9750MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ13897MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-2176
GTTS-WQ7727MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GLP-1Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW